Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial. This is an ASCO Meeting Abstract from the 2025 ...

The FDA has granted accelerated approval to Beqalzi (sonrotoclax), the first BCL2 inhibitor approved for adults with relapsed or refractory mantle cell lymphoma (MCL), an aggressive form ...

Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...

Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated. To ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...

Nasreen, who accompanied her husband on the show, shared how he has been a rock-solid support during the crisis.

Transcription: Colleen Moretti: What is relapsed/refractory multiple myeloma? How does it differ from typical disease? Dr. Saad Usmani: Relapsed and/or refractory myeloma is myeloma that has come back ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...